Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 186

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies

Open access
Kornegay, Joe N., Bogan, Janet R., Bogan, Daniel J., Childers, Martin K., Li, Juan, Nghiem, Peter, Detwiler, David A., Larsen, C. Aaron, Grange, Robert W., Bhavaraju-Sanka, Ratna K., Tou, Sandra, Keene, Bruce P., Howard, James F., Wang, Jiahui, Fan, Zheng, Schatzberg, Scott J., Styner, Martin A., Flanigan, Kevin M., Xiao, Xiao, Hoffman, Eric P. · 2012 · Mammalian Genome

Abstract

Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder in which the loss of dystrophin causes progressive degeneration of skeletal and cardiac muscle. Potential therapies that carry substantial risk, such as gene- and cell-based approaches, must first be tested in animal models, notably the mdx mouse and several dystrophin-deficient breeds of dogs, including golden retriever muscular dystrophy (GRMD). Affected dogs have a more severe phenotype, in keeping with that of DMD, so may better predict disease pathogenesis and treatment efficacy. Various phenotypic tests have been developed to characterize disease progression in the GRMD model. These biomarkers range from measures of strength and joint contractures to magnetic resonance imaging. Some of these tests are routinely used in clinical veterinary practice, while others require specialized equipment and expertise. By comparing serial measurements from treated and untreated groups, one can document improvement or delayed progression of disease. Potential treatments for DMD may be broadly categorized as molecular, cellular, or pharmacologic. The GRMD model has increasingly been used to assess efficacy of a range of these therapies. A number of these studies have provided largely general proof-of-concept for the treatment under study. Others have demonstrated efficacy using the biomarkers discussed. Importantly, just as symptoms in DMD vary among patients, GRMD dogs display remarkable phenotypic variation. Though confounding statistical analysis in preclinical trials, this variation offers insight regarding the role that modifier genes play in disease pathogenesis. By correlating functional and mRNA profiling results, gene targets for therapy development can be identified.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00335-011-9382-y

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 186

Metadata

Authors
Kornegay, J. N., Bogan, J. R., Bogan, D. J., Childers, M. K., Li, J., Nghiem, P., Detwiler, D. A., Larsen, C. A., Grange, R. W., Bhavaraju-Sanka, R. K., Tou, S., Keene, B. P., Howard, J. F., Wang, J., Fan, Z., Schatzberg, S. J., Styner, M. A., Flanigan, K. M., Xiao, X., & Hoffman, E. P.
Venue
Mammalian Genome
Published
2012-01-05
Volume
23
Issue
1-2
Pages
85-108
ISSN
  • 0938-8990 (ISSN-L)
  • 1432-1777
OpenAlex
W1982858450
Cited by
186
References
11
FWCI
6.97
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. https://app.cochat.ai/papers/10.1007/s00335-011-9382-y
The paper
Kornegay, J. N., Bogan, J. R., Bogan, D. J., Childers, M. K., Li, J., Nghiem, P., Detwiler, D. A., Larsen, C. A., Grange, R. W., Bhavaraju-Sanka, R. K., Tou, S., Keene, B. P., Howard, J. F., Wang, J., Fan, Z., Schatzberg, S. J., Styner, M. A., Flanigan, K. M., Xiao, X., & Hoffman, E. P. (2012). Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mammalian Genome. https://doi.org/10.1007/s00335-011-9382-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.